Neosoma
Aug 17, 2023
Neosoma Announced Today That It Has Achieved SOC 2 Type II Compliance
Neosoma, a leading provider of medical technology solutions to advance the treatment of brain cancers, announced today that it has achieved SOC 2 Type II compliance in accordance with American Institute of Certified Public Accountants (AICPA) standards for SOC for Service Organizations, also known as SSAE 18.
Safeguarding customer and patient data is paramount to Neosoma’s mission, and the SOC 2 independent review process serves as third-party industry validation that Neosoma provides enterprise-level security and management of customer data secured in the company’s systems. Receiving an unqualified opinion on a SOC 2 Type II audit report is a significant achievement and demonstrates Neosoma’s commitment and adherence to the highest data security standards.
Michael Hill, Neosoma’s Chief Technical Officer, who led the company’s SOC 2 compliance efforts, said, “Working in the SAMD space, we understand the criticality of securely managing our customer data and have built our platform with this as a priority every step of the way. Having this attestation provides transparency into our process and allows our customers to feel confident that their patient information stays safe while we provide them with Neosoma’s unique analytical disease insights.”
About Neosoma
Neosoma is focused on advancing the treatment of brain cancers through an integrated portfolio of innovative, artificial intelligence-based software products combined with a Clinical Management Software Platform.
The Neosoma comprehensive SaaS solution is first-of-its-kind technology in the neuro-oncology space, helping physicians to make better treatment decisions with the goal of improving clinical outcomes.